Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
Endocrinology · 2022
DOI: 10.17925/ee.2022.18.1.43 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinology, 2022. Verfasst von David M Williams und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This article is published under the Creative Commons Attribution Non-commercial License..
Abstract (Originalsprache)
There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective therapies for obesity. Glucagon-like peptide-1 receptor analogues (GLP-1RAs) are licensed for the treatment of type 2 diabetes (T2D), and there is substantial evidence that these drugs not only improve cardiovascular outcomes but also promote weight loss. More recent evidence supports the use of the GLP-1RAs liraglutide and semaglutide in people with obesity without T2D. This article discusses the results of the major cardiovascular outcome trials for GLP-1RAs in people with T2D, the SCALE Obesity and Prediabetes study (Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE™ - Obesity and Pre-diabetes; ClinicalTrials.gov identifier: NCT01272219; investigating liraglutide) and the STEP studies (Semaglutide treatment effect in people with obesity; assorted studies; investigating subcutaneous semaglutide). We also highlight the importance of a cost-effective approach to obesity pharmacotherapy. Clinicians should consider the use of GLP-1RAs in people with obesity, especially those with T2D or other obesity-related diseases, such as hypertension and dyslipidaemia. Ongoing trials, as well as clinical and cost-effectiveness appraisals, are anticipated over the next 12 months, and their findings may change the current landscape of obesity pharmacotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK.
- Diabetes Research Group, Swansea University Medical School, Swansea University, Swansea, UK.
- Department of Diabetes and Endocrinology, Neath Port Talbot Hospital, Swansea Bay University Health Board, Swansea, UK.
Förderung
- This article is published under the Creative Commons Attribution Non-commercial License.
Zitieren
APA
Williams, D. M., Staff, M., Bain, S. C., & Min, T. (2022). Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. Endocrinology. https://doi.org/10.17925/ee.2022.18.1.43
Vancouver
Williams DM, Staff M, Bain SC, Min T. Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. Endocrinology. 2022. doi:10.17925/ee.2022.18.1.43
BibTeX
@article{Williams2022,
author = {Williams, David M and Staff, Matthew and Bain, Stephen C and Min, Thinzar},
title = {Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity},
journal = {Endocrinology},
year = {2022},
doi = {10.17925/ee.2022.18.1.43}
}
EUVIMED